Top Premarket Decliners

MT Newswires Live

Nov 01, 2024

ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide.

Lexicon Pharmaceuticals (LXRX) stock tumbled 37%, after saying late Thursday that the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee said the company's Zynquista inhibitor's benefits do not "outweigh" the risks in adults having type 1 diabetes and chronic kidney disease.

DigitalBridge Group (DBRG) shares were down 6% after it reported lower Q3 distributable earnings and total revenue compared with a year earlier.

Telephone and Data Systems (TDS) stock slipped nearly 6% after it reported a wider Q3 net loss and lower revenue compared with last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2480073580"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480073580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2480073580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480073580","market":"sh","top_or_hot":-1,"title":"Top Premarket Decliners","media":"MT Newswires Live","content":"<html><body><p> ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide.</p><p>Lexicon Pharmaceuticals (LXRX) stock tumbled 37%, after saying late Thursday that the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee said the company's Zynquista inhibitor's benefits do not \"outweigh\" the risks in adults having type 1 diabetes and chronic kidney disease.</p><p>DigitalBridge Group (DBRG) shares were down 6% after it reported lower Q3 distributable earnings and total revenue compared with a year earlier.</p><p>Telephone and Data Systems (TDS) stock slipped nearly 6% after it reported a wider Q3 net loss and lower revenue compared with last year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Premarket Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Premarket Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-01 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide.</p><p>Lexicon Pharmaceuticals (LXRX) stock tumbled 37%, after saying late Thursday that the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee said the company's Zynquista inhibitor's benefits do not \"outweigh\" the risks in adults having type 1 diabetes and chronic kidney disease.</p><p>DigitalBridge Group (DBRG) shares were down 6% after it reported lower Q3 distributable earnings and total revenue compared with a year earlier.</p><p>Telephone and Data Systems (TDS) stock slipped nearly 6% after it reported a wider Q3 net loss and lower revenue compared with last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPIX","symbol_name":"ESSA Pharma Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2480073580","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480073580","pubTimestamp":1730463342,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamid","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPIX":"ESSA Pharma Inc.","BK4139":"生物科技","BK4233":"房地产运营公司","BK4132":"无线电信业务","BK4205":"房地产经营公司","TDS":"电话数据","BK4135":"资产管理与托管银行","LXRX":"莱斯康制药","BK4160":"多样化房地产投资信托v","DBRG":"DigitalBridge Group, Inc."},"translate_title":"盘前跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDS":0.9,"DBRG":0.9,"EPIX":0.9,"LXRX":0.9},"content_text":"ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide.Lexicon Pharmaceuticals (LXRX) stock tumbled 37%, after saying late Thursday that the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee said the company's Zynquista inhibitor's benefits do not \"outweigh\" the risks in adults having type 1 diabetes and chronic kidney disease.DigitalBridge Group (DBRG) shares were down 6% after it reported lower Q3 distributable earnings and total revenue compared with a year earlier.Telephone and Data Systems (TDS) stock slipped nearly 6% after it reported a wider Q3 net loss and lower revenue compared with last year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}